47 results on '"McMeekin, D. Scott"'
Search Results
2. A phase 1b dose escalation study of ipafricept (OMP 54F28) in combination with paclitaxel and carboplatin in patients with recurrent platinum-sensitive ovarian cancer
3. The pro-inflammatory effect of obesity on high grade serous ovarian cancer
4. Primary and acquired platinum-resistance among women with high grade serous ovarian cancer
5. Initiation of a formalized precision medicine program in gynecologic oncology
6. A phase I study of IV doxorubicin plus intraperitoneal (IP) paclitaxel and IV or IP cisplatin in endometrial cancer patients at high risk for peritoneal failure (GOG 9920): An NRG Oncology/Gynecologic Oncology Group study
7. Do Radiation Delivery and Outcomes Differ With Obesity in Locoregionally Advanced Cervix Cancer?
8. A phase II trial of brivanib in recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group Study
9. The survival detriment of venous thromboembolism with epithelial ovarian cancer
10. Measurements of adiposity as clinical biomarkers for first-line bevacizumab-based chemotherapy in epithelial ovarian cancer
11. Referrals to phase I clinical trials in a gynecologic oncology unit
12. Phase II trial of vaginal cuff brachytherapy followed by chemotherapy in early stage endometrial cancer patients with high-intermediate risk factors
13. Inpatient versus outpatient management of neutropenic fever in gynecologic oncology patients: Is risk stratification useful?
14. Corrigendum to “A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: A Gynecologic Oncology Group study” [Gynecol Oncol 127 (2012) 538–543]
15. Etiologic heterogeneity in endometrial cancer: Evidence from a Gynecologic Oncology Group trial
16. A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: A Gynecologic Oncology Group study
17. A phase II trial of thalidomide in patients with refractory uterine carcinosarcoma and correlation with biomarkers of angiogenesis: A Gynecologic Oncology Group study
18. Designing the next lymphadenectomy trial: What should we learn for our prior experiences
19. A phase I study of concurrent weekly topotecan and cisplatin chemotherapy with whole pelvic radiation therapy in locally advanced cervical cancer: A gynecologic oncology group study
20. What should lymphadenectomy offer in early-stage endometrial cancer: lots of variables, little control
21. Phase II trial of intraperitoneal cisplatin combined with intravenous paclitaxel in patients with ovarian, primary peritoneal and fallopian tube cancer
22. Phase II trial of cetuximab in the treatment of persistent or recurrent squamous or non-squamous cell carcinoma of the cervix: A Gynecologic Oncology Group study
23. A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: A Gynecologic Oncology Group Study
24. Health-related quality of life outcomes associated with four cisplatin-based doublet chemotherapy regimens for stage IVB recurrent or persistent cervical cancer: A Gynecologic Oncology Group study
25. Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: A Gynecologic Oncology Group study
26. A phase II evaluation of pemetrexed (Alimta, LY231514, IND #40061) in the treatment of recurrent or persistent endometrial carcinoma: A phase II study of the Gynecologic Oncology
27. Response to “Residual tumor after neoadjuvant chemotherapy and interval debulking for advanced endometrial cancer”
28. Vulvar cancer in young women: demographic features and outcome evaluation
29. Stage IVB endometrial cancer: Does applying an ovarian cancer treatment paradigm result in similar outcomes? A case-control analysis
30. Phase I trial of the treatment of high-risk endometrial cancer with concurrent weekly paclitaxel and cisplatin and whole abdominal radiation therapy: A Gynecologic Oncology Group study
31. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass
32. Ovarian cancer in the octogenarian: Does the paradigm of aggressive cytoreductive surgery and chemotherapy still apply?
33. Comparison of outcome measures in patients with advanced squamous cell carcinoma of the vulva treated with surgery or primary chemoradiation
34. Extraperitoneal para-aortic lymph node evaluation for cervical cancer via pfannenstiel incision: Technique and peri-operative outcomes
35. A phase II trial of thalidomide in patients with refractory leiomyosarcoma of the uterus and correlation with biomarkers of angiogenesis: A gynecologic oncology group study
36. Vesicovaginal fistula formation in patients with Stage IVA cervical carcinoma
37. Gynecologic Oncology Group risk groups for vulvar carcinoma: Improvement in survival in the modern era
38. The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: A Gynecologic Oncology Group study
39. A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: A Gynecologic Oncology Group study
40. Sequence dependence of hematologic toxicity using carboplatin and topotecan for primary therapy of advanced epithelial ovarian cancer: A phase I study of the Gynecologic Oncology Group
41. Clinical results and quality of life analysis for the MVAC combination (methotrexate, vinblastine, doxorubicin, and cisplatin) in carcinoma of the uterine cervix: A Gynecologic Oncology Group study
42. Cisplatin plus gemcitabine in previously treated squamous cell carcinoma of the cervix: A phase II study of the Gynecologic Oncology Group
43. Preoperative predictors of positive margins after loop electrosurgical excisional procedure–Cone
44. Carcinosarcoma of the ovary—a case series
45. Role of pegylated liposomal doxorubicin in ovarian cancer
46. A comparison of stages IB1 and IB2 cervical cancers treated with radical hysterectomy. Is size the real difference?
47. Timing isn't everything: an analysis of when to start salvage chemotherapy in ovarian cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.